Novalis Biotech is an early stage venture capital fund in life sciences. The firm’s investment ideas focus on the interaction between bio-informatics and life sciences. The firm strongly believes in applying innovative information technology to advance prevention, diagnosis, or treatment of diseases. Novalis focuses on capital light business models and platform technology. As an early stage private equity/venture capital fund, they are a dynamic and flexible player not restricting themselves to specific fields of expertise, but open to discuss any proposition in the field of life-sciences. The firm differentiates themselves by high dynamism and flexibility to rapidly evolve their portfolio companies. 
 
Novalis Biotech is interested in the diagnostics and digital health sectors. Within diagnostics, the firm is opportunistic and will consider technologies, services, and tools in development phases. Within digital health, the firm is opportunistic with interests including bioinformatics. The firm does not invest in clinical trials and will not consider traditional pharmaceuticals or medtech sectors. Indications of interest include oncology and neurology. 
 
Novalis Biotech highly values working with a top management team that is committed to the project. The firm acts as a lead investor and will require board seating. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A holding company manages an early-stage life sciences fund focused exclusively on private companies developing pharmaceutical products. The firm invests globally in early-stage programs, preferably with proof-of-concept validation, and supports companies from venture creation through Series A.  

Investments are made in the form of straight equity, with capital deployed over the life of the company. The firm is science-driven, may lead or co-invest, seeks board representation, and takes an active role in guiding company development and strategy. The firm does not target a fixed number of investments per year. 

In addition to the early-stage strategy, the firm also manages a late-stage vehicle focused on private pharmaceutical companies raising Series B through crossover or IPO rounds. 

Across both strategies, the firm is open to preclinical and clinical-stage therapeutic companies and is agnostic to modality and indication. The firm invests exclusively in first-in-class, breakthrough assets and does not consider repurposed drugs, diagnostics, medical devices, or incremental technologies. 

The firm prefers to invest early and support companies through major value inflection points. The firm does not impose specific requirements regarding management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A strategic corporate venture capital fund makes equity investments in startup companies developing innovative therapeutic products and drug-enabling platform technologies with clear potential to benefit cancer patients. Investment size is flexible depending on the opportunity. In addition to traditional equity investments, the firm may consider option-based structures and spin-outs. The firm seeks opportunities primarily in US and Europe.  

The firm focuses on early-stage opportunities, generally from research through pre-IND, targeting first-in-class or new biology-based drug discovery approaches and innovative platform technologies. The firm prioritizes assets with strategic alignment to the parent organization’s pipeline. The firm evaluates a broad range of modalities, including biologics, oncolytic viruses, and small molecules, and considers cell and gene therapy on an opportunistic basis. The primary therapeutic focus is oncology, with additional interest in immunology, allergy, musculoskeletal, and orphan indications. 

While the firm is primarily therapeutics-focused, the firm may selectively review medical device, diagnostic, or digital health technologies where there is strong strategic alignment. 

From a company and management team perspective, the firm seeks teams with strong sector expertise. With the backing of an established oncology development organization, the firm provides financial support and facilitates strategic partnerships to help advance novel research and high-potential drug candidates toward commercialization. The firm may request regional options or rights on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A pre-Seed and Seed-stage venture capital firm is focused on AI and next-generation computing technologies applied to large industries. The firm prefers to invest in companies located in North America.  

The firm partners with entrepreneurs addressing real-world problems through data and machine learning, with a focus on frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Prior investment areas have included biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, automated pathology solutions, and related technologies. 

From a company and management team perspective, the firm seeks experienced teams with a strong long-term vision. The firm may take a board seat when the firm brings specific domain expertise relevant to the company. The firm does not have a fixed equity ownership target. The firm values strong technical teams with deep market understanding and is comfortable partnering with very early-stage companies, including those at the pre-product stage. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm is focused on investing in breakthrough technologies that aim to prevent disease and extend healthspan and lifespan. The firm’s investment sweet spot is at the Seed stage and the firm may consider Series A opportunities on a case-by-case basis. Typical check sizes are around $1M, with the ability to invest up to $5M. The firm is open to opportunities globally, with a particular focus on Europe and the United States. The firm generally does not lead investment rounds or take board seats but provides active support to portfolio companies.  

The firm seeks to invest in genuinely innovative and differentiated therapeutics and digital health opportunities. Within therapeutics, the firm prefers areas outside of oncology, with a focus on novel biological targets. Areas of particular interest include aging-related technologies, especially regenerative or reversal approaches rather than simple lifespan extension. Within digital health, the firm is interested in consumer-facing technologies that improve accessibility to healthcare.  

The firm is open to engaging at very early stages, including lab spinouts. The firm does not impose specific requirements on companies or management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a venture capital firm focused on investments across life sciences, healthcare, and advanced technology sectors. The firm invests in biopharmaceuticals, diagnostics, medical devices, digital health, functional foods, and AI-driven technologies, as well as convergent applications spanning areas such as autonomous systems, robotics, semiconductors, energy, and telecommunications. The firm manages multiple investment vehicles and continues to expand its investment activities through successive funds.  

Historically, the firm has invested primarily in domestic companies but is actively seeking new investment opportunities in the United States.  

Within life sciences and healthcare, the firm invests across biopharmaceuticals, diagnostics, medical devices, digital health, and functional foods. The firm also supports AI-enabled and cross-disciplinary technologies that bridge healthcare with advanced engineering and data-driven innovation. Within biopharmaceuticals, the firm evaluates both preclinical and clinical-stage companies developing innovative therapeutic and diagnostic solutions.  

From a company and management team perspective, the firm prioritizes businesses built on strong fundamental technologies with sustainable growth potential. The firm favors teams that demonstrate technical excellence, long-term commitment, and the ability to execute effective commercialization strategies. The firm emphasizes close partnership with founders who are resilient, innovation-driven, and oriented toward building globally competitive companies, and provides active support from early development through later-stage growth and exit. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.